US20140322201A1 - Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies - Google Patents

Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies Download PDF

Info

Publication number
US20140322201A1
US20140322201A1 US14/139,096 US201314139096A US2014322201A1 US 20140322201 A1 US20140322201 A1 US 20140322201A1 US 201314139096 A US201314139096 A US 201314139096A US 2014322201 A1 US2014322201 A1 US 2014322201A1
Authority
US
United States
Prior art keywords
antibody
huluc63
seq
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/139,096
Inventor
Daniel Afar
Kenneth C. Anderson
Yu-Tzu TAI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Biotherapeutics Inc
Original Assignee
AbbVie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Biotherapeutics Inc filed Critical AbbVie Biotherapeutics Inc
Priority to US14/139,096 priority Critical patent/US20140322201A1/en
Publication of US20140322201A1 publication Critical patent/US20140322201A1/en
Priority to US14/834,077 priority patent/US20160137735A1/en
Priority to HUS1600043C priority patent/HUS1600043I1/en
Priority to US15/670,681 priority patent/US20170342150A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Definitions

  • MM Multiple myeloma
  • the terms multiple myeloma and myeloma are used interchangeably to refer to the same condition.
  • the myeloma tumor, its products, and the host response to it result in a number of organ dysfunctions and symptoms of bone pain or fracture, renal failure, susceptibility to infection, anemia, hypocalcemia, and occasionally clotting abnormalities, neurologic symptoms and vascular manifestations of hyperviscosity. See D. Longo, in Harrison's Principles of Internal Medicine 14th Edition, p. 713 (McGraw-Hill, New York, 1998). No effective long-term treatment currently exists for MM.
  • MM malignant disease of plasma cells, manifested as hyperproteinemia, anemia, renal dysfunction, bone lesions, and immunodeficiency. MM is difficult to diagnose early because there may be no symptoms in the early stage. The disease has a progressive course with a median duration of survival of six months when no treatment is given. Systemic chemotherapy is the main treatment, and the current median of survival with chemotherapy is about three years, however fewer than 5% live longer than 10 years (See Anderson, K. et al., Annual Meeting Report 1999. Recent Advances in the Biology and Treatment of Multiple Myeloma (1999)).
  • CS1 CD2-subset1
  • SLAMF7 SLAMF7
  • CRACC CRACC
  • 19A APEX-1
  • FOAP12 FOAP12
  • anti-CS1 antibodies exhibit significant anti-myeloma activity (see, e.g., U.S. Patent Publication Nos. 2005/0025763 and 2006/0024296, the contents of which are incorporated herein by reference).
  • HuLuc63 effectively mediates lysis of myeloma cells via antibody dependent cellular cytotoxicity (ADCC) (see, e.g., U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference).
  • ADCC antibody dependent cellular cytotoxicity
  • HuLuc63 significantly reduced tumor mass by more than 50% (see, e.g., U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference).
  • the present disclosure relates to compositions and methods for treating patients diagnosed with Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory.
  • the methods relate to the administration of a pharmaceutical composition comprising an anti-CS1 antibody, such as HuLuc63, in combination with one or more therapeutic agents.
  • the anti-CS1 antibody is typically administered in a first pharmaceutical composition as an intravenous infusion at doses ranging from 0.5 to 20 mg/kg, from once a week to once a month.
  • a second pharmaceutical composition comprising one or more therapeutic agents, such as bortezomib and lenalidomide, can be administered concurrently, prior to, or following administration of an anti-CS1 antibody.
  • the composition can be administered orally, intravenously or subcutaneously.
  • Therapeutic agents can be used at high dose rates, standard dose rates and at reduced dose rates.
  • administration of the pharmaceutical compositions described herein increases the sensitivity of multiple myeloma cells to a therapeutic agent.
  • inclusion of an anti-CS1 antibody can enhance the activity of the therapeutic agent, such that lower doses can be used in the compositions and methods described herein.
  • administration of the pharmaceutical compositions described herein elicits at least one of the beneficial responses as defined by the European Group for Blood and Marrow transplantation (EBMT).
  • EBMT European Group for Blood and Marrow transplantation
  • administration of the pharmaceutical compositions described herein can result in a complete response, partial response, minimal response, no change, or plateau.
  • FIGS. 1A-1C depict autologous ADCC-mediated lysis of MM cells treated with HuLuc63;
  • FIGS. 2A-2B depict HuLuc63 induced ADCC against Hsp90 and bortezomib resistant patient tumor cells
  • FIGS. 3A-3C depict enhancement of HuLuc63 induced ADCC against MM cells when effector cells were pretreated with lenalidomide
  • FIGS. 4A-4D depict the effect of bortezomib pre-treatment on HuLuc63-mediated ADCC in vitro. Examples are shown for 4 different donors; and,
  • FIGS. 5A-5B depict the effect of HuLuc63 and bortezomib in OPM2 tumor-bearing mice.
  • compositions described herein combine anti-CS1 antibodies with one or more therapeutic agents at specific doses to potentiate or complement the anti-myeloma activities of the other.
  • suitable anti-CS1 antibodies include, but are not limited to, isolated antibodies that bind one or more of the three epitope clusters identified on CS1 and monoclonal antibodies produced by the hybridoma cell lines: Luc2, Luc3, Luc15, Luc22, Luc23, Luc29, Luc32, Luc34, Luc35, Luc37, Luc38, Luc39, Luc56, Luc60, Luc63, Luc69, LucX.1, LucX.2 or Luc90.
  • suitable anti-CS1 antibodies include isolated antibodies that bind one or more of the three epitope clusters identified on CS1 (SEQ ID NO: 1, Table 1 below; see, e.g., U.S. Patent Publication No. 2006/0024296, the content of which is incorporated herein by reference). As disclosed in U.S. Patent Publication No. 2006/0024296 and shown below in Table 1, the CS1 antibody binding sites have been grouped into 3 epitope clusters:
  • the pharmaceutical compositions include the anti-CS1 antibody HuLuc63.
  • HuLuc63 is a humanized recombinant monoclonal IgG1 antibody directed to human CS1.
  • the amino acid sequence for the heavy chain variable region (SEQ ID NO: 5) and the light chain variable region (SEQ ID NO: 6) for HuLuc63 is disclosed in U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference, and in Table 1.
  • the synergistic effect permits one or more therapeutic agents to be administered in combination with one or more anti-CS1 antibodies at a reduced dosage, while retaining efficacy.
  • use of the compositions and methods described herein can reduce the deleterious side effects observed in conventional and novel treatment regimens used to treat MM when these agents are administered at their recommended dosages.
  • the synergistic effect permits one or more therapeutic agents to be administered in combination with one or more anti-CS1 antibodies at the approved dosage, but with greater than the expected efficacy.
  • compositions can be administered for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory.
  • MGUS Monoclonal Gammopathy of Undetermined Significance
  • smoldering myeloma asymptomatic MM
  • symptomatic MM ranging from newly diagnosed to late stage relapsed/refractory.
  • administration of the compositions results in a reduction in M-protein in serum or urine such that a plateau, no change, minimal, partial or complete response is observed as defined by the European Group for Blood and Marrow transplantation (EBMT).
  • EBMT European Group for Blood and Marrow transplantation
  • compositions that are beneficial in reducing tumor mass and/or regressing tumor growth, in patients diagnosed with multiple myeloma.
  • the components of the pharmaceutical compositions are addressed in more detail below, but typically include an anti-CS1 antibody, such as HuLuc63 and one or more therapeutic agents.
  • an anti-CS1 antibody can be provided in a first pharmaceutical composition, and a therapeutic agent provided in a second composition.
  • an anti-CS1 antibody can be provided in a first pharmaceutical composition, one therapeutic agent can be provided in a second composition and the other therapeutic agent can be provided in a third composition.
  • an anti-CS1 antibody can be provided in one pharmaceutical composition and the therapeutic agents can be combined and provided in a second pharmaceutical composition.
  • one composition, comprising an anti-CS1 antibody combined with one or more therapeutic agents can be provided.
  • an anti-CS1 antibody is present in a pharmaceutical composition at a concentration sufficient to permit intravenous administration at 0.5 mg/kg to 20 mg/kg.
  • the concentration of HuLuc63 suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.5 mg/kg, at least about 0.75 mg/kg, at least about 1 mg/kg, at least about 2 mg/kg, at least about 2.5 mg/kg, at least about 3 mg/kg, at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, at least about 12 mg/kg, at least about 13 mg/kg, at least about 14 mg/kg, at least about 15 mg/kg, at least about 16 mg/kg, at least about 17 mg/kg, at least about 18 mg/kg, at least about 19 mg/kg, and at least about 20
  • the anti-CS1 antibodies can be administered in single or multiple dose regimens. Generally, an anti-CS1 antibody is administered over a period of time from about 1 to about 24 hours, but is typically administered over a period of about 1 to 2 hours. Dosages can be repeated from about 1 to about 4 weeks or more, for a total of 4 or more doses. Typically, dosages are repeated once every week, once every other week, or once a month, for a minimum of 4 doses to a maximum of 52 doses.
  • Determination of the effective dosage, total number of doses, and length of treatment with an anti-CS1 antibody is well within the capabilities of those skilled in the art, and can be determined using a standard dose escalation study to identify the maximum tolerated dose (MTD) (see, e.g., Richardson et al., 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • MTD maximum tolerated dose
  • one or more therapeutic agents are administered in combination with an anti-CS1 antibody.
  • the agents can be administered concurrently, prior to, or following administration of an anti-CS1 antibody.
  • an anti-CS1 antibody is administered prior to the administration of the therapeutic agents.
  • an anti-CS1 antibody can be administered approximately 0 to 60 days prior to the administration of the therapeutic agents.
  • an anti-CS1 antibody such as HuLuc63, is administered from about 30 minutes to about 1 hour prior to the administration of the therapeutic agents, or from about 1 hour to about 2 hours prior to the administration of the therapeutic agents, or from about 2 hours to about 4 hours prior to the administration of the therapeutic agents, or from about 4 hours to about 6 hours prior to the administration of the therapeutic agents, or from about 6 hours to about 8 hours prior to the administration of the therapeutic agents, or from about 8 hours to about 16 hours prior to the administration of the therapeutic agents, or from about 16 hours to 1 day prior to the administration of the therapeutic agents, or from about 1 to 5 days prior to the administration of the therapeutic agents, or from about 5 to 10 days prior to the administration of the therapeutic agents, or from about 10 to 15 days prior to the administration of the therapeutic agents, or from about 15 to 20 days prior to the administration of the therapeutic agents.
  • an anti-CS1 antibody is administered concurrently with the administration of the therapeutic agents.
  • an anti-CS1 antibody is administered following the administration of the therapeutic agents.
  • an anti-CS1 antibody such as HuLuc63
  • HuLuc63 can be administered approximately 0 to 60 days after the administration of the therapeutic agents.
  • HuLuc63 is administered from about 30 minutes to about 1 hour following the administration of the therapeutic agents, or from about 1 hour to about 2 hours following the administration of the therapeutic agents, or from about 2 hours to about 4 hours following the administration of the therapeutic agents, or from about 4 hours to about 6 hours following the administration of the therapeutic agents, or from about 6 hours to about 8 hours following the administration of the therapeutic agents, or from about 8 hours to about 16 hours following the administration of the therapeutic agents, or from about 16 hours to 1 day following the administration of the therapeutic agents, or from about 1 to 5 days following the administration of the therapeutic agents, or from about 5 to 10 days following the administration of the therapeutic agents, or from about 10 to 15 days following the administration of the therapeutic agents, or from about 15 to 20 days following the administration of the therapeutic agents, or from about 20 to 30 days following the administration of the therapeutic agents
  • the therapeutic agents can be administered in any manner found appropriate by a clinician and are typically provided in generally accepted efficacious dose ranges, such as those described in the Physician Desk Reference, 56th Ed. (2002), Publisher Medical Economics, New Jersey.
  • a standard dose escalation can be performed to identify the maximum tolerated dose (MTD) (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • doses less than the generally accepted efficacious dose of a therapeutic agent can be used.
  • the composition comprises a dosage that is less than about 10% to 75% of the generally accepted efficacious dose range.
  • at least about 10% or less of the generally accepted efficacious dose range is used, at least about 15% or less, at least about 25%, at least about 30% or less, at least about 40% or less, at least about 50% or less, at least about 60% or less, at least about 75% or less, and at least about 90%.
  • the therapeutic agents can be administered singly or sequentially, or in a cocktail with other therapeutic agents, as described below.
  • the therapeutic agents can be administered orally, intravenously, systemically by injection intramuscularly, subcutaneously, intrathecally or intraperitoneally.
  • therapeutic agents that can be used in the compositions described herein include, but are not limited to, dexamethasone, thalidomide, melphalan, prednisone, doxorubicin, doxorubicin HCL liposome injection, bortezomib, lenalidomide, and/or combinations thereof.
  • two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide.
  • two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising a therapeutically effective amount of bortezomib.
  • At least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide and a therapeutically effective amount of bortezomib.
  • lenalidomide and bortezomib are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising lenalidomide, and a third comprising bortezomib.
  • At least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide and dexamethasone.
  • lenalidomide and dexamethasone are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising lenalidomide, and a third comprising dexamethasone.
  • At least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of bortezomib and dexamethasone.
  • bortezomib and dexamethasone are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising bortezomib, and a third comprising dexamethasone.
  • compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising therapeutically effective amount of lenalidomide, bortezomib, and dexamethasone.
  • lenalidomide, bortezomib, and dexamethasone are provided separately.
  • compositions comprising other combinations can be prepared, depending in part, on dosage, route of administration, and whether the agents are provided in a solid, semi-solid or liquid form.
  • compositions can be made: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, a second comprising dexamethasone, and a third comprising lenalidomide and bortezomib.
  • an anti-CS1 antibody such as HuLuc63
  • a second comprising dexamethasone
  • a third comprising lenalidomide and bortezomib.
  • compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising a therapeutically effective amount of bortezomib and optionally can comprise one or more of the following agents: thalidomide, dexamethasone, melphalan, doxorubicin, doxorubicin HCl liposome injection, and/or prednisone.
  • an anti-CS1 antibody such as HuLuc63
  • bortezomib optionally can comprise one or more of the following agents: thalidomide, dexamethasone, melphalan, doxorubicin, doxorubicin HCl liposome injection, and/or prednisone.
  • compositions comprising various combinations of thalidomide, dexamethasone, melphalan, doxorubicin, doxorubicin HCl liposome injection, and prednisone can be prepared depending in part, on dosage, route of administration, and whether the agents are provided in a solid, semi-solid or liquid form.
  • compositions can exist as a solid, semi-solid, or liquid (e.g., suspensions or aerosols) dosage form.
  • the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts.
  • anti-CS1 antibodies can be packaged in dosages ranging from about 1 to 1000 mg.
  • anti-CS1 antibodies can be packaged in a dosage at least about 1 mg, at least about 10 mg, at least about 20 mg, at least about 50 mg, at least about 100 mg, at least about 200 mg, at least about 300 mg, at least about 400 mg, at least about 500 mg, at least about 750 mg, at least about 1000 mg.
  • compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, nontoxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration.
  • diluents are selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution.
  • composition or formulation can also include other carriers, adjuvants, or nontoxic, non-therapeutic, nonimmunogenic stabilizers and the like. Effective amounts of such diluent or carrier will be those amounts that are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components, or biological activity.
  • compositions described herein find use in treating MM.
  • the compositions can be used to treat Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory.
  • MGUS Monoclonal Gammopathy of Undetermined Significance
  • smoldering myeloma asymptomatic MM
  • symptomatic MM ranging from newly diagnosed to late stage relapsed/refractory.
  • compositions can be combined with other treatment strategies, i.e., autologous stem cell transplantation and allogeneic effector cell transplantation, to develop an effective treatment strategy based on the stage of myeloma being treated (see, e.g., Multiple Myeloma Research Foundation, Multiple Myeloma: Stem Cell Transplantation 1-30 (2004); U.S. Pat. Nos. 6,143,292, and 5,928,639, Igarashi, et al. Blood 2004, 104(1): 170-177, Maloney, et al. 2003, Blood, 102(9): 3447-3454, Badros, et al. 2002, J Clin Oncol., 20:1295-1303, Tricot, et al. 1996, Blood, 87(3):1196-1198; the contents of which are incorporated herein by reference).
  • other treatment strategies i.e., autologous stem cell transplantation and allogeneic effector cell transplantation
  • A relatively normal renal function
  • B abnormal renal function, creatinine value ⁇ 2.0 mg/dL
  • ISS International Staging System
  • IPI international prognostic index
  • the ISS is based on the assessment of two blood test results, beta 2 -microglobulin ( ⁇ 2 -M) and albumin, which separates patients into three prognostic groups irrespective of type of therapy.
  • EBMT European Group for Blood and Marrow transplantation
  • bone marrow plasma cells should increase by >25% and at least 10% in absolute terms; MRI examination may be helpful in selected patients.
  • a “near complete response” is defined as the criteria for a “complete response” (CR), but with a positive immunofixation test.
  • a “very good partial response” is defined as a greater than 90% decrease in M protein (see, e.g., Multiple Myeloma Research Foundation, Multiple Myeloma: Treatment Overview 9 (2005)).
  • the degree to which administration of the compositions elicits a response in an individual clinically manifesting at least one symptom associated with MM depends in part, on the severity of disease, e.g., Stage I, II, or III, and in part, on whether the patient is newly diagnosed or has late stage refractory MM. Thus, in some embodiments, administration of the pharmaceutical composition elicits a complete response.
  • administration of the pharmaceutical composition elicits a very good partial response or a partial response.
  • administration of the pharmaceutical composition elicits a minimal response.
  • administration of the pharmaceutical composition prevents the disease from progressing, resulting in a response classified as “no change” or “plateau” by the EBMT.
  • compositions comprising an anti-CS1 antibody and one or more therapeutic agents for treating individuals diagnosed with MM can be determined using art-standard techniques, such as a standard dose escalation study to identify the MTD (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • anti-CS1 antibodies are administered intravenously.
  • Administration of the other therapeutic agents described herein can be by any means known in the art. Such means include oral, rectal, nasal, topical (including buccal and sublingual) or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and will depend in part, on the available dosage form. For example, therapeutic agents that are available in a pill or capsule format typically are administered orally.
  • oral administration generally requires administration of a higher dose than does intravenous administration. Determination of the actual route of administration that is best in a particular case is well within the capabilities of those skilled in the art, and in part, will depend on the dose needed versus the number of times per month administration is required.
  • Factors affecting the selected dosage of an anti-CS1 antibody and the therapeutic agents used in the compositions and methods described herein include, but are not limited to, the type of agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy.
  • the selected dosage should be sufficient to result in no change, but preferably results in at least a minimal change.
  • An effective amount of a pharmaceutical agent is that which provides an objectively identifiable response, e.g., minimal, partial, or complete, as noted by the clinician or other qualified observer, and as defined by the EBMT.
  • an anti-CS1 antibody such as HuLuc63
  • the therapeutic agents can each be administered as a separate composition, or combined in a cocktail and administered as a single combined composition.
  • the compositions comprising an anti-CS1 antibody and one or more therapeutic agents are administered concurrently.
  • an anti-CS1 antibody can be administered prior to the administration of composition(s) comprising the therapeutic agent(s).
  • an anti-CS1 antibody is administered following the administration of composition(s) comprising the therapeutic agent(s).
  • an anti-CS1 antibody is administered prior to or following the administration of the therapeutic agents
  • determination of the duration between the administration of an anti-CS1 antibody and administration of the agents is well within the capabilities of those skilled in the art, and in part, will depend on the dose needed versus the number of times per month administration is required.
  • Doses of anti-CS1 antibodies used in the methods described herein typically range between 0.5 mg/kg to 20 mg/kg.
  • Optimal doses for the therapeutic agents are the generally accepted efficacious doses, such as those described in the Physician Desk Reference, 56th Ed. (2002), Publisher Medical Economics, New Jersey.
  • Optimal doses for agents not described in the Physician Desk Reference can be determined using a standard dose escalation study to identify the MTD (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the contents of which are incorporated herein by reference).
  • an anti-CS1 antibody is present in a pharmaceutical composition at a concentration, or in a weight/volume percentage, or in a weight amount, suitable for intravenous administration at a dosage rate at least about 0.5 mg/kg, at least about 0.75 mg/kg, at least about 1 mg/kg, at least about 2 mg/kg, at least about 2.5 mg/kg, at least about 3 mg/kg, at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, at least about 12 mg/kg, at least about 13 mg/kg, at least about 14 mg/kg, at least about 15 mg/kg, at least about 16 mg/kg, at least about 17 mg/kg, at least about 18 mg/kg, at least about 19 mg/kg, and at least about 20 mg/kg.
  • Lenalidomide is the first of a new class of oral cancer drugs called IMiDs®. These immunomodulatory derivatives are chemically similar to thalidomide but are more potent and have a different side effect profile than thalidomide. They have multiple mechanisms of action that affect both the cancer cell and its microenvironment. Lenalidomide has been shown to induce immune responses, enhance activity of immune cells, and inhibit inflammation. For example, lenalidomide may enhance the activation of T cells and NK cells, induce production of interleukin 2 and inhibit pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin 1-beta. Currently lenalidomide in combination with dexamethasone is approved for 2 nd line therapy of multiple myeloma.
  • ADCC was measured by calcein-AM release assay, with sensitivity similar to traditional Cr 51 assay, as described previously.
  • peripheral blood mononuclear cells PBMCs
  • NK natural killer
  • Increasing concentrations (0-10 ⁇ g/ml) of either HuLuc63 or human isotype control IgG 1 MSL109 mAbs were added at effector: target (E:T) ratios of 20:1, in a final volume of 200 ⁇ l per well.
  • E:T effector: target
  • PBMC effector cells were pretreated with lenalidomide for 3 days at 0.2 ⁇ M before HuLuc63-mediated ADCC assays were performed.
  • HuLuc63-mediated lysis of patient MM cells by effector cells from the same patient was measured using an ADCC assay.
  • HuLuc63, but not iso IgG 1 induced significant autologous myeloma cell lysis in patients in patient samples ( FIGS. 1A-1C ).
  • HuLuc63-mediated autologous tumor cell lysis was also demonstrated in patients with MM resistant or refractory to novel anti-MM therapies including bortezomib and/or 17-AAG (targeting heat shock protein 90) ( FIGS. 2A and 2B ). These data suggest that HuLuc63 can target myeloma cells from patients that are newly diagnosed, or resistant to standard of care drugs and/or novel agents.
  • HuLuc63-mediated lysis of patient myeloma cells by PBMC effector cells from the same patient was measured using an ADCC assay.
  • CD138-purified tumor cells from a patient with MM were incubated with autologous effector cells in the presence of serial dilutions of HuLuc63 (solid symbols) or isotype control IgG 1 (open symbols).
  • PBMC effector cells were pre-incubated for 3 days in the presence or absence of with lenalidomide (0.2 mM) (square symbols) or vehicle control (round symbols), followed by HuLuc63-mediated ADCC.
  • HuLuc63-mediated ADCC but not iso IgG 1 , induced significant autologous myeloma cell lysis in a patient sample.
  • Bortezomib is a potent, specific, and reversible proteasome inhibitor. Proteasomes are present in all cells and function to help regulate cell growth. Inhibition of the proteasome results in apoptosis of cancer cells. Bortezomib has been shown to be particularly effective at killing myeloma cells and is currently approved for 2 nd and 3 rd line therapy in multiple myeloma. Recent data has shown that bortezomib treatment of myeloma cells results in down-modulation of cell-surface expression of MHC class I, an inhibitor of NK function (Shi et al., Blood (ASH Annual Meeting Abstracts), November 2006; 108:3498).
  • OPM2 myeloma cells were harvested at mid-log phase, suspended at a density of 1.0 ⁇ 10 6 cells/mL in complete media (RPMI with 10% FBS) and treated overnight with or without Velcade (10 nM). Cells were collected, washed, re-suspended at a density of 20 ⁇ 106 viable cells/mL, and labeled for one hour with 50 mCi Na 2 [ 51 Cr]O 4 per 10 6 cells. 51 Cr-Labeled cells were washed then added to a 96-well V-bottomed polystyrene plate at a cell density of 15,000 cells per 75 ⁇ L RPMI supplemented with 10% heat-inactivated FBS.
  • HuLuc63 and a human IgG 1 isotype control antibody MSL-109 were added to target cells for a final antibody concentration ranging from 0.001 to 10 ⁇ g/mL.
  • NK cells were enriched from the whole blood of healthy donors using the RosetteSep human NK cell enrichment cocktail (Stem Cell Technologies). The enriched NK cells were added to Velcade treated or untreated OPM2 cells at a ratio of 10:1. After a 4-hour incubation at 37° C., cells were centrifuged and the supernatants measured for released 51 Cr. Maximum release was determined from target cells lysed with 100 mg/ml Digitonin.
  • AICC Antibody independent cellular cytotoxicity
  • % Cytotoxicity was calculated as((sample ⁇ AICC)/(Maximum ⁇ AICC)*100.
  • CS1 protein expression was examined on the OPM2 multiple myeloma cell line with no significant change in CS1 expression observed pre- or post-treatment with HuLuc63, bortezomib or with both agents.
  • the combination of HuLuc63 with bortezomib was then tested for anti-myeloma activity in vitro using ADCC assays.
  • the results showed that pre-treatment with bortezomib significantly enhanced HuLuc63-mediated ADCC towards OPM2 cells using NK effector cells from healthy donors.
  • OPM2 cells were pretreated with vehicle control (square symbols) or bortezomib (10 nM; round symbols) for 18 hrs and were then subjected to HuLuc63 mediated ADCC using human NK cells from healthy donors.
  • HuLuc63 (closed symbols) and isotype control antibody (open symbols) were used at doses ranging from 0.001-10 ⁇ g/ml.
  • the results show that bortezomib pre-treatment significantly decreased the EC 50 for HuLuc63-mediated ADCC in vitro ( FIGS. 4A-4D , Table 3).
  • IcrTac:ICR-Prkdc scid mice obtained from Taconic Farms (Germantown, N.Y.) were inoculated with 1 ⁇ 10 7 OPM2 (American Type Culture Collection) cells into the lower right flank. Caliper measurements were performed twice weekly to calculate tumor volume using the following formula: L ⁇ W ⁇ H/2, where L (length) is the longest side of the tumor in the plane of the animal's back, W (width) is the longest measurement perpendicular to the length and in the same plane and H (height) is taken at the highest point perpendicular to the back of the animal.
  • mice were randomized into 3 groups of 8-10 mice each and were treated with 1 mg/kg of antibody administered intraperitoneally twice a week for a total of 6 doses.
  • Bortezomib was administered intraperitoneally at a dose of 0.75 mg/kg twice a week for a total of 6 doses.
  • Tumor growth was monitored for a period of 1-2 months.
  • Animal work was carried out under NIH guidelines (“Guide for the Care and Use of Laboratory Animals”) using protocols approved by IACUC at PDL BioPharma.
  • HuLuc63 was combined with bortezomib in vivo, using a different dose and dosing schedule for bortezomib, while keeping the original HuLuc63 dose and dosing schedule.
  • OPM2 cells were inoculated into the flanks of SCID mice. When tumors reached an average size of about 100 mm3, animals were randomized into 4 groups of 15 mice each and were treated with 1 mg/kg of antibody administered intraperitoneally twice a week for a total of 10 doses.
  • Bortezomib was administered intraperitoneally at a dose of 1 mg/kg twice for weeks 1 and 2, no treatment for week 3, and 1 mg/kg twice for weeks 4 and 5 for a total of 8 doses.
  • mice in the combination treatment group exhibited significantly smaller tumors than mice treated with either drug alone.
  • the data indicates that bortezomib synergizes with HuLuc63 in anti-myeloma tumor activity.
  • the proposed Phase 1b, multi-center, open-label, multi-dose, dose escalation study will evaluate the combination of HuLuc63 and bortezomib in patients with multiple myeloma after 1st or 2nd relapse.
  • HuLuc63 will be given by intravenous injection (IV) at up to five dose levels ranging from 2.5 mg/kg to 20 mg/kg in combination with a fixed dose of bortezomib IV at 1.0 mg/m2.
  • Patients will receive HuLuc63 every 10 days and bortezomib will be given in 21-day cycles (twice weekly for two weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12-21)).
  • EBMT criteria will be assessed. If a patient has progressive disease, HuLuc63 will be discontinued and bortezomib may be withdrawn or continued at the discretion of the site investigator. If the patient has responded or has stable disease at Week 9, dosing with HuLuc63 and bortezomib will continue so that a total of 24 weeks of treatment (16 doses HuLuc63, 8 cycles bortezomib) are completed or disease progression occurs. Dosing with HuLuc63 and bortezomib will continue until the data from the Week 9 visit are available.
  • Dosing cohorts are as follows: 2.5 mg/kg HuLuc63/1.3 mg/m 2 bortezomib; 5 mg/kg HuLuc63/1.3 mg/m 2 bortezomib; 10 mg/kg HuLuc63/1.3 mg/m 2 bortezomib; 15 mg/kg HuLuc63/1.3 mg/m 2 bortezomib; and, 20 mg/kg HuLuc63/1.3 mg/m 2 bortezomib.
  • HuLuc63 will be provided at a concentration of 10 mg/mL in an intravenous formulation in vials.
  • Bortezomib will be provided as a 3.5 mg lyophilized cake or powder in a 10 mL vial, to be reconstituted with 3.5 mL normal (0.9%) saline, sodium chloride injection to 3.5 mL of 1 mg/mL of bortezomib, as per Velcade® package insert.
  • Approximately 15 to 30 patients in 5 cohorts will be enrolled in the trial. Each cohort will begin with 3 patients. If no dose-limiting toxicity (DLT) is noted within the first 6 weeks of treatment in any patient, enrollment will begin in the next higher cohort. If one patient has a DLT, 3 additional patients will be enrolled in the cohort. If no other patient in the cohort has a DLT, escalation to the next cohort may proceed. If a second patient in a cohort has a DLT, the maximum tolerated dose (MTD) has been reached.
  • DLT dose-limiting toxicity
  • a dose-limiting toxicity is defined using the National Cancer Center Institute Common Toxicity Criteria Version 3.0 (NCI CTCAE v3.0) as a grade 4 hematologic toxicity or hyperbilirubinemia, or a grade 3 toxicity in any other system considered related to HuLuc63 or the combination of HuLuc63 and bortezomib.
  • NCI CTCAE v3.0 National Cancer Center Institute Common Toxicity Criteria Version 3.0
  • 3 assessable patients must complete their first 6 weeks (4 doses HuLuc63, 2 cycles bortezomib). If a DLT occurs, an additional three assessable patients will be accrued. Patients will be monitored for safety by assessing adverse events categorized by NCI CTCAE v3.0 and patients will be monitored for clinical activity using EBMT.
  • the maximally tolerated dose is defined as the highest dose studied for which the incidence of DLTs is ⁇ 33%.
  • the highest tolerated dose will be HuLuc63 20 mg/kg+bortezomib 1.0 mg/m 2 if no dose limiting toxicities are observed.
  • the proposed Phase 1b, multi-center, open-label, multi-dose, dose escalation study will evaluate the combination of HuLuc63 and lenalidomide in patients with multiple myeloma after 1st or 2nd relapse.
  • HuLuc63 will be given by intravenous injection (IV) at up to five dose levels ranging from 2.5 mg/kg to 20 mg/kg in combination with a fixed dose of lenalidomide PO at 15 mg.
  • Patients will receive HuLuc63 every 7 days and lenalidomide will be given in 28-day cycles (once daily for 21 days followed by a 7-day rest period (days 22-28)).
  • EBMT criteria will be assessed.
  • Dexamethasone will be added to the regimen at an oral dose of 40 mg daily on days 1, 8, 15 and 22 of a 4-week cycle. If at week 12 (12 doses HuLuc63, 3 cycles of lenalidomide, 1 cycle of dexamethasone) there is evidence of progressive disease, HuLuc63 will be stopped and lenalidomide and dexamethasone will be continued up to 16 weeks at the discretion of the investigator. If a patient has stable disease or better, they will continue on HuLuc63 until week 16 (15 total doses) or disease progression. EMBT criteria will be evaluated at week 16.
  • HuLuc63 IV once every 10 days, with each dose infused over 1 hour.
  • Lenalidomide will be given orally daily for 3 weeks followed by a weeklong rest period.
  • Dosing cohorts are as follows: 2.5 mg/kg HuLuc63/15 mg lenalidomide; 5 mg/kg HuLuc63/15 mg lenalidomide; 10 mg/kg HuLuc63/15 mg lenalidomide; 15 mg/kg HuLuc63/15 mg lenalidomide; and, 20 mg/kg HuLuc63/15 mg lenalidomide.
  • dexamethasone will be added to the above regimens at an oral dose of 40 mg daily on days 1, 8, 15 and 22 of a 4 week cycle.
  • HuLuc63 will be provided at a concentration of 10 mg/mL in an intravenous formulation in vials.
  • Lenalidomide will be supplied as 5 mg and 10 mg capsules for oral administration.
  • Approximately 15 to 30 patients in 5 cohorts will be enrolled in the trial. Each cohort will begin with 3 patients. If no dose-limiting toxicity (DLT) is noted within the first 4 weeks of treatment in any patient, enrollment will begin in the next higher cohort. If one patient has a DLT, 3 additional patients will be enrolled in the cohort. If no other patient in the cohort has a DLT, escalation to the next cohort may proceed. If a second patient in a cohort has a DLT, the maximum tolerated dose (MTD) has been reached.
  • DLT dose-limiting toxicity
  • a dose-limiting toxicity is defined using the National Cancer Center Institute Common Toxicity Criteria Version 3.0 (NCI CTCAE v3.0) as a grade 4 hematologic toxicity or hyperbilirubinemia, or a grade 3 toxicity in any other system considered related to HuLuc63 or the combination of HuLuc63 and lenalidomide.
  • NCI CTCAE v3.0 National Cancer Center Institute Common Toxicity Criteria Version 3.0
  • 3 assessable patients must complete their first 4 weeks (4 doses HuLuc63, 1 cycle lenalidomide). If a DLT occurs, an additional three assessable patients will be accrued. Patients will be monitored for safety by assessing adverse events categorized by NCI CTCAE v3.0 and patients will be monitored for clinical activity using EBMT.
  • the maximally tolerated dose is defined as the highest dose studied for which the incidence of DLTs is ⁇ 33%.
  • the highest tolerated dose will be HuLuc63 20 mg/kg+lenalidomide 15 mg if no dose limiting toxicities are observed.

Abstract

Compositions and methods for treating MM are provided herein.

Description

    1. CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of application Ser. No. 11/835,257, filed Aug. 7, 2007, now U.S. Pat. No. 8,632,772, which claims benefit under 35 U.S.C. §119(e) to application Ser. No. 60/836,185, filed Aug. 7, 2006 and 60/944,262, filed Jun. 15, 2007, the contents of which are incorporated herein by reference.
    • 2. BACKGROUND
  • Multiple myeloma (“MM”) represents a malignant proliferation of plasma cells derived from a single clone. The terms multiple myeloma and myeloma are used interchangeably to refer to the same condition. The myeloma tumor, its products, and the host response to it result in a number of organ dysfunctions and symptoms of bone pain or fracture, renal failure, susceptibility to infection, anemia, hypocalcemia, and occasionally clotting abnormalities, neurologic symptoms and vascular manifestations of hyperviscosity. See D. Longo, in Harrison's Principles of Internal Medicine 14th Edition, p. 713 (McGraw-Hill, New York, 1998). No effective long-term treatment currently exists for MM. It is a malignant disease of plasma cells, manifested as hyperproteinemia, anemia, renal dysfunction, bone lesions, and immunodeficiency. MM is difficult to diagnose early because there may be no symptoms in the early stage. The disease has a progressive course with a median duration of survival of six months when no treatment is given. Systemic chemotherapy is the main treatment, and the current median of survival with chemotherapy is about three years, however fewer than 5% live longer than 10 years (See Anderson, K. et al., Annual Meeting Report 1999. Recent Advances in the Biology and Treatment of Multiple Myeloma (1999)).
  • While multiple myeloma is considered to be a drug-sensitive disease, almost all patients with MM who initially respond to chemotherapy eventually relapse (See Anderson, K. et al., Annual Meeting Report 1999. Recent Advances in the Biology and Treatment of Multiple Myeloma (1999)). Since the introduction of melphalan and prednisone therapy for MM, numerous multi-drug chemotherapies including Vinca alkaloid, anthracycline, and nitrosourea-based treatment have been tested (See Case, D C et al., (1977) Am. J. Med 63:897 903), but there has been little improvement in outcome over the past three decades (See Case, D C et al., (1977) Am. J. Med 63:897 903; Otsuki, T. et al, (2000) Cancer Res. 60:1). New methods of treatment, such as combination therapies utilizing monoclonal antibodies and therapeutic agents, are needed.
    • 3. SUMMARY
  • Described herein are compositions and methods useful for exploiting the anti-tumor properties of anti-CS1 antibodies. Anti-CS1 antibodies that can be used in the methods and compositions are described in U.S. Patent Publication Nos. 2005/0025763 and 2006/0024296, the contents of which are incorporated herein by reference. The anti-CS1 antibodies target CS1 (CD2-subset1), which is also known as SLAMF7, CRACC, 19A, APEX-1, and FOAP12 (Genbank Accession Number NM—021181.3). CS1, is a glycoprotein that is highly expressed in bone marrow samples from patients diagnosed with MM. In both in vitro and in vivo studies, anti-CS1 antibodies exhibit significant anti-myeloma activity (see, e.g., U.S. Patent Publication Nos. 2005/0025763 and 2006/0024296, the contents of which are incorporated herein by reference). By way of example, but not limitation, the anti-CS1 antibody, HuLuc63 effectively mediates lysis of myeloma cells via antibody dependent cellular cytotoxicity (ADCC) (see, e.g., U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference). In a myeloma mouse tumor model, treatment with HuLuc63 significantly reduced tumor mass by more than 50% (see, e.g., U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference).
  • The present disclosure relates to compositions and methods for treating patients diagnosed with Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory. In particular, the methods relate to the administration of a pharmaceutical composition comprising an anti-CS1 antibody, such as HuLuc63, in combination with one or more therapeutic agents. The anti-CS1 antibody is typically administered in a first pharmaceutical composition as an intravenous infusion at doses ranging from 0.5 to 20 mg/kg, from once a week to once a month.
  • A second pharmaceutical composition comprising one or more therapeutic agents, such as bortezomib and lenalidomide, can be administered concurrently, prior to, or following administration of an anti-CS1 antibody. Depending on the agent, the composition can be administered orally, intravenously or subcutaneously. Therapeutic agents can be used at high dose rates, standard dose rates and at reduced dose rates.
  • In some embodiments, administration of the pharmaceutical compositions described herein increases the sensitivity of multiple myeloma cells to a therapeutic agent. By way of example, but not limitation, inclusion of an anti-CS1 antibody can enhance the activity of the therapeutic agent, such that lower doses can be used in the compositions and methods described herein.
  • In some embodiments, administration of the pharmaceutical compositions described herein elicits at least one of the beneficial responses as defined by the European Group for Blood and Marrow transplantation (EBMT). For example, administration of the pharmaceutical compositions described herein can result in a complete response, partial response, minimal response, no change, or plateau.
    • 4. BRIEF DESCRIPTION OF THE FIGURES
  • FIGS. 1A-1C depict autologous ADCC-mediated lysis of MM cells treated with HuLuc63;
  • FIGS. 2A-2B depict HuLuc63 induced ADCC against Hsp90 and bortezomib resistant patient tumor cells;
  • FIGS. 3A-3C depict enhancement of HuLuc63 induced ADCC against MM cells when effector cells were pretreated with lenalidomide;
  • FIGS. 4A-4D depict the effect of bortezomib pre-treatment on HuLuc63-mediated ADCC in vitro. Examples are shown for 4 different donors; and,
  • FIGS. 5A-5B depict the effect of HuLuc63 and bortezomib in OPM2 tumor-bearing mice.
    •  5. DETAILED DESCRIPTION
  • The compositions described herein combine anti-CS1 antibodies with one or more therapeutic agents at specific doses to potentiate or complement the anti-myeloma activities of the other. Examples of suitable anti-CS1 antibodies include, but are not limited to, isolated antibodies that bind one or more of the three epitope clusters identified on CS1 and monoclonal antibodies produced by the hybridoma cell lines: Luc2, Luc3, Luc15, Luc22, Luc23, Luc29, Luc32, Luc34, Luc35, Luc37, Luc38, Luc39, Luc56, Luc60, Luc63, Luc69, LucX.1, LucX.2 or Luc90. These monoclonal antibodies are named as the antibodies: Luc2, Luc3, Luc15, Luc22, Luc23, Luc29, Luc32, Luc34, Luc35, Luc37, Luc38, Luc39, Luc56, Luc60, Luc63, Luc69, LucX and Luc90, respectively, hereafter. Humanized versions are denoted by the prefix “hu” (see, e.g., U.S. Patent Publication Nos. 2005/0025763 and 2006/0024296, the contents of which are incorporated herein by reference).
  • In some embodiments, suitable anti-CS1 antibodies include isolated antibodies that bind one or more of the three epitope clusters identified on CS1 (SEQ ID NO: 1, Table 1 below; see, e.g., U.S. Patent Publication No. 2006/0024296, the content of which is incorporated herein by reference). As disclosed in U.S. Patent Publication No. 2006/0024296 and shown below in Table 1, the CS1 antibody binding sites have been grouped into 3 epitope clusters:
      • (1) the epitope defined by Luc90, which binds to hu50/mu50 (SEQ ID NO: 2). This epitope covers from about amino acid residue 23 to about amino acid residue 151 of human CS1. This epitope is resided within the domain 1 (V domain) of the extracellular domain. This epitope is also recognized by Luc34, LucX (including LucX.1 and LucX.2) and Luc69.
      • (2) the epitope defined by Luc38, which binds to mu25/hu75 (SEQ ID NO: 3) and hu50/mu50 (SEQ ID NO: 81). This epitope likely covers from about amino acid residue 68 to about amino acid residue 151 of human CS1. This epitope is also recognized by Luc5.
      • (3) the epitope defined by Luc 63, which binds to mu75/hu25 (SEQ ID NO: 4). This epitope covers from about amino acid residue 170 to about amino acid residue 227 of human CS1. This epitope is resided within domain 2 (C2 domain) of human CS1. This epitope is also recognized by Luc4, Luc12, Luc23, Luc29, Luc32 and Luc37.
  • The methods and pharmaceutical compositions are addressed in more detail below, but typically include at least one anti-CS1 antibody as described above. In some embodiments, the pharmaceutical compositions include the anti-CS1 antibody HuLuc63. HuLuc63 is a humanized recombinant monoclonal IgG1 antibody directed to human CS1. The amino acid sequence for the heavy chain variable region (SEQ ID NO: 5) and the light chain variable region (SEQ ID NO: 6) for HuLuc63 is disclosed in U.S. Patent Publication No. 2005/0025763, the content of which is incorporated herein by reference, and in Table 1.
  • TABLE 1
    SEQ ID
    NO: Amino Acid Sequence
    SEQ ID Met Ala Gly Ser Pro Thr Cys Leu Thr Leu Ile
    NO: 1 Tyr Ile Leu Trp Gln Leu Thr Gly Ser Ala Ala
    Ser Gly Pro Val Lys Glu Leu Val Gly Ser Val
    Gly Gly Ala Val Thr Phe Pro Leu Lys Ser Lys
    Val Lys Gln Val Asp Ser Ile Val Trp Thr Phe
    Asn Thr Thr Pro Leu Val Thr Ile Gln Pro Glu
    Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn
    Arg Glu Arg Val Asp Phe Pro Asp Gly Gly Tyr
    Ser Leu Lys Leu Ser Lys Leu Lys Lys Asn Asp
    Ser Gly Ile Tyr Tyr Val Gly Ile Tyr Ser Ser
    Ser Leu Gln Gln Pro Ser Thr Gln Glu Tyr Val
    Leu His Val Tyr Glu His Leu Ser Lys Pro Lys
    Val Thr Met Gly Leu Gln Ser Asn Lys Asn Gly
    Thr Cys Val Thr Asn Leu Thr Cys Cys Met Glu
    His Gly Glu Glu Asp Val Ile Tyr Thr Trp Lys
    Ala Leu Gly Gln Ala Ala Asn Glu Ser His Asn
    Gly Ser Ile Leu Pro Ile Ser Trp Arg Trp Gly
    Glu Ser Asp Met Thr Phe Ile Cys Val Ala Arg
    Asn Pro Val Ser Arg Asn Phe Ser Ser Pro Ile
    Leu Ala Arg Lys Leu Cys Glu Gly Ala Ala Asp
    Asp Pro Asp Ser Ser Met Val Leu Leu Cys Leu
    Leu Leu Val Pro Leu Leu Leu Ser Leu Phe Val
    Leu Gly Leu Phe Leu Trp Phe Leu Lys Arg Glu
    Arg Gln Glu Glu Tyr Ile Glu Glu Lys Lys Arg
    Val Asp Ile Cys Arg Glu Thr Pro Asn Ile Cys
    Pro His Ser Gly Glu Asn Thr Glu Tyr Asp Thr
    Ile Pro His Thr Asn Arg Thr Ile Leu Lys Glu
    Asp Pro Ala Asn Thr Val Tyr Ser Thr Val Glu
    Ile Pro Lys Lys Met Glu Asn Pro His Ser Leu
    Leu Thr Met Pro Asp Thr Pro Arg Leu Phe Ala
    Tyr Glu Asn Val Ile
    SEQ ID Met Ala Gly Ser Pro Thr Cys Leu Thr Leu Ile
    NO: 2 Tyr Ile Leu Trp Gln Leu Thr Gly Ser Ala Ala
    Ser Gly Pro Val Lys Glu Leu Val Gly Ser Val
    Gly Gly Ala Val Thr Phe Pro Leu Lys Ser Lys
    Val Lys Gln Val Asp Ser Ile Val Trp Thr Phe
    Asn Thr Thr Pro Leu Val Thr Ile Gln Pro Glu
    Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn
    Arg Glu Arg Val Asp Phe Pro Asp Gly Gly Tyr
    Ser Leu Lys Leu Ser Lys Leu Lys Lys Asn Asp
    Ser Gly Ile Tyr Tyr Val Gly Ile Tyr Ser Ser
    Ser Leu Gln Gln Pro Ser Thr Gln Glu Tyr Val
    Leu His Val Tyr Glu His Leu Ser Lys Pro Lys
    Val Thr Ile Asp Arg Gln Ser Asn Lys Asn Gly
    Thr Cys Val Ile Asn Leu Thr Cys Ser Thr Asp
    Gln Asp Gly Glu Asn Val Thr Tyr Ser Trp Lys
    Ala Val Gly Gln Gly Asp Asn Gln Phe His Asp
    Gly Ala Thr Leu Ser Ile Ala Trp Arg Ser Gly
    Glu Lys Asp Gln Ala Leu Thr Cys Met Ala Arg
    Asn Pro Val Ser Asn Ser Phe Ser Thr Pro Val
    Phe Pro Gln Lys Leu Cys Glu Asp Ala Ala Thr
    Asp Leu Thr Ser Leu Arg Gly
    SEQ ID Met Ala Arg Phe Ser Thr Tyr Ile Ile Phe Thr
    NO: 3 Ser Val Leu Cys Gln Leu Thr Val Thr Ala Ala
    Ser Gly Thr Leu Lys Lys Val Ala Gly Ala Leu
    Asp Gly Ser Val Thr Phe Thr Leu Asn Ile Thr
    Glu Ile Lys Val Asp Tyr Val Val Trp Thr Phe
    Asn Thr Phe Phe Leu Ala Met Val Lys Lys Asp
    Gly Gly Thr Ile Ile Val Thr Gln Asn Arg Asn
    Arg Glu Arg Val Asp Phe Pro Asp Gly Gly Tyr
    Ser Leu Lys Leu Ser Lys Leu Lys Lys Asn Asp
    Ser Gly Ile Tyr Tyr Val Gly Ile Tyr Ser Ser
    Ser Leu Gln Gln Pro Ser Thr Gln Glu Tyr Val
    Leu His Val Tyr Glu His Leu Ser Lys Pro Lys
    Val Thr Met Gly Leu Gln Ser Asn Lys Asn Gly
    Thr Cys Val Thr Asn Leu Thr Cys Cys Met Glu
    His Gly Glu Glu Asp Val Ile Tyr Thr Trp Lys
    Ala Leu Gly Gln Ala Ala Asn Glu Ser His Asn
    Gly Ser Ile Leu Pro Ile Ser Trp Arg Trp Gly
    Glu Ser Asp Met Thr Phe Ile Cys Val Ala Arg
    Asn Pro Val Ser Arg Asn Phe Ser Ser Pro Ile
    Leu Ala Arg Lys Leu Cys Glu Gly Ala Ala Asp
    Asp Pro Asp Ser Ser Met Val
    SEQ ID Met Ala Arg Phe Ser Thr Tyr Ile Ile Phe Thr
    NO: 4 Ser Val Leu Cys Gln Leu Thr Val Thr Ala Ala
    Ser Gly Thr Leu Lys Lys Val Ala Gly Ala Leu
    Asp Gly Ser Val Thr Phe Thr Leu Asn Ile Thr
    Glu Ile Lys Val Asp Tyr Val Val Trp Thr Phe
    Asn Thr Phe Phe Leu Ala Met Val Lys Lys Asp
    Gly Val Thr Ser Gln Ser Ser Asn Lys Glu Arg
    Ile Val Phe Pro Asp Gly Leu Tyr Ser Met Lys
    Leu Ser Gln Leu Lys Lys Asn Asp Ser Gly Ala
    Tyr Arg Ala Glu Ile Tyr Ser Thr Ser Ser Gln
    Ala Ser Leu Ile Gln Glu Tyr Val Leu His Val
    Tyr Lys His Leu Ser Arg Pro Lys Val Thr Ile
    Asp Arg Gln Ser Asn Lys Asn Gly Thr Cys Val
    Ile Asn Leu Thr Cys Ser Thr Asp Gln Asp Gly
    Glu Asn Val Thr Tyr Ser Trp Lys Ala Val Gly
    Gln Ala Ala Asn Glu Ser His Asn Gly Ser Ile
    Leu Pro Ile Ser Trp Arg Trp Gly Glu Ser Asp
    Met Thr Phe Ile Cys Val Ala Arg Asn Pro Val
    Ser Arg Asn Phe Ser Ser Pro Ile Leu Ala Arg
    Lys Leu Cys Glu Gly Ala Ala Asp Asp Pro Asp
    Ser Ser Met Val
    SEQ ID Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu
    NO: 5 Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys
    Ala Ala Ser Gly Phe Asp Phe Ser Arg Tyr Trp
    Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly
    Leu Glu Trp Ile Gly Glu Ile Asn Pro Asp Ser
    Ser Thr Ile Asn Tyr Ala Pro Ser Leu Lys Asp
    Lys Phe Ile Ile Ser Arg Asp Asn Ala Lys Asn
    Ser Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala
    Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Pro
    Asp Gly Asn Tyr Trp Tyr Phe Asp Val Trp Gly
    Gln Gly Thr Leu Val Thr Val Ser Ser
    SEQ ID Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu
    NO: 6 Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
    Cys Lys Ala Ser Gln Asp Val Gly Ile Ala Val
    Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro
    Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg His
    Thr Gly Val Pro Asp Arg Phe Ser Gly Ser Gly
    Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
    Leu Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys
    Gln Gln Tyr Ser Ser Tyr Pro Tyr Thr Phe Gly
    Gln Gly Thr Lys Val Glu Ile Lys
  • At some doses, additive effects are seen; at other doses, synergistic effects are seen. In some embodiments, the synergistic effect permits one or more therapeutic agents to be administered in combination with one or more anti-CS1 antibodies at a reduced dosage, while retaining efficacy. Given that the side effects associated with the use of these agents are dose-dependent, use of the compositions and methods described herein can reduce the deleterious side effects observed in conventional and novel treatment regimens used to treat MM when these agents are administered at their recommended dosages.
  • In other embodiments, the synergistic effect permits one or more therapeutic agents to be administered in combination with one or more anti-CS1 antibodies at the approved dosage, but with greater than the expected efficacy.
  • The compositions can be administered for the treatment of Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory. Typically, administration of the compositions results in a reduction in M-protein in serum or urine such that a plateau, no change, minimal, partial or complete response is observed as defined by the European Group for Blood and Marrow transplantation (EBMT).
  • 5.2 Pharmaceutical Compositions
  • Provided herein are pharmaceutical compositions that are beneficial in reducing tumor mass and/or regressing tumor growth, in patients diagnosed with multiple myeloma. The components of the pharmaceutical compositions are addressed in more detail below, but typically include an anti-CS1 antibody, such as HuLuc63 and one or more therapeutic agents. In some embodiments, the various components of the compositions are provided separately. For example, an anti-CS1 antibody can be provided in a first pharmaceutical composition, and a therapeutic agent provided in a second composition. When the composition comprises two or more therapeutic agents, an anti-CS1 antibody can be provided in a first pharmaceutical composition, one therapeutic agent can be provided in a second composition and the other therapeutic agent can be provided in a third composition. In other embodiments, an anti-CS1 antibody can be provided in one pharmaceutical composition and the therapeutic agents can be combined and provided in a second pharmaceutical composition. In still other embodiments, one composition, comprising an anti-CS1 antibody combined with one or more therapeutic agents can be provided.
  • In typical embodiments, an anti-CS1 antibody is present in a pharmaceutical composition at a concentration sufficient to permit intravenous administration at 0.5 mg/kg to 20 mg/kg. In some embodiments, the concentration of HuLuc63 suitable for use in the compositions and methods described herein includes, but is not limited to, at least about 0.5 mg/kg, at least about 0.75 mg/kg, at least about 1 mg/kg, at least about 2 mg/kg, at least about 2.5 mg/kg, at least about 3 mg/kg, at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, at least about 12 mg/kg, at least about 13 mg/kg, at least about 14 mg/kg, at least about 15 mg/kg, at least about 16 mg/kg, at least about 17 mg/kg, at least about 18 mg/kg, at least about 19 mg/kg, and at least about 20 mg/kg.
  • The anti-CS1 antibodies can be administered in single or multiple dose regimens. Generally, an anti-CS1 antibody is administered over a period of time from about 1 to about 24 hours, but is typically administered over a period of about 1 to 2 hours. Dosages can be repeated from about 1 to about 4 weeks or more, for a total of 4 or more doses. Typically, dosages are repeated once every week, once every other week, or once a month, for a minimum of 4 doses to a maximum of 52 doses.
  • Determination of the effective dosage, total number of doses, and length of treatment with an anti-CS1 antibody is well within the capabilities of those skilled in the art, and can be determined using a standard dose escalation study to identify the maximum tolerated dose (MTD) (see, e.g., Richardson et al., 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • In some embodiments, one or more therapeutic agents are administered in combination with an anti-CS1 antibody. The agents can be administered concurrently, prior to, or following administration of an anti-CS1 antibody.
  • In some embodiments, an anti-CS1 antibody is administered prior to the administration of the therapeutic agents. For example, an anti-CS1 antibody can be administered approximately 0 to 60 days prior to the administration of the therapeutic agents. In some embodiments, an anti-CS1 antibody, such as HuLuc63, is administered from about 30 minutes to about 1 hour prior to the administration of the therapeutic agents, or from about 1 hour to about 2 hours prior to the administration of the therapeutic agents, or from about 2 hours to about 4 hours prior to the administration of the therapeutic agents, or from about 4 hours to about 6 hours prior to the administration of the therapeutic agents, or from about 6 hours to about 8 hours prior to the administration of the therapeutic agents, or from about 8 hours to about 16 hours prior to the administration of the therapeutic agents, or from about 16 hours to 1 day prior to the administration of the therapeutic agents, or from about 1 to 5 days prior to the administration of the therapeutic agents, or from about 5 to 10 days prior to the administration of the therapeutic agents, or from about 10 to 15 days prior to the administration of the therapeutic agents, or from about 15 to 20 days prior to the administration of the therapeutic agents, or from about 20 to 30 days prior to the administration of the therapeutic agents, or from about 30 to 40 days prior to the administration of the therapeutic agents, and from about 40 to 50 days prior to the administration of the therapeutic agents, or from about 50 to 60 days prior to the administration of the therapeutic agents.
  • In some embodiments, an anti-CS1 antibody is administered concurrently with the administration of the therapeutic agents.
  • In some embodiments, an anti-CS1 antibody is administered following the administration of the therapeutic agents. For example, an anti-CS1 antibody, such as HuLuc63, can be administered approximately 0 to 60 days after the administration of the therapeutic agents. In some embodiments, HuLuc63 is administered from about 30 minutes to about 1 hour following the administration of the therapeutic agents, or from about 1 hour to about 2 hours following the administration of the therapeutic agents, or from about 2 hours to about 4 hours following the administration of the therapeutic agents, or from about 4 hours to about 6 hours following the administration of the therapeutic agents, or from about 6 hours to about 8 hours following the administration of the therapeutic agents, or from about 8 hours to about 16 hours following the administration of the therapeutic agents, or from about 16 hours to 1 day following the administration of the therapeutic agents, or from about 1 to 5 days following the administration of the therapeutic agents, or from about 5 to 10 days following the administration of the therapeutic agents, or from about 10 to 15 days following the administration of the therapeutic agents, or from about 15 to 20 days following the administration of the therapeutic agents, or from about 20 to 30 days following the administration of the therapeutic agents, or from about 30 to 40 days following the administration of the therapeutic agents, and from about 40 to 50 days following the administration of the therapeutic agents, or from about 50 to 60 days following the administration of the therapeutic agents.
  • The therapeutic agents can be administered in any manner found appropriate by a clinician and are typically provided in generally accepted efficacious dose ranges, such as those described in the Physician Desk Reference, 56th Ed. (2002), Publisher Medical Economics, New Jersey. In other embodiments, a standard dose escalation can be performed to identify the maximum tolerated dose (MTD) (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • In some embodiments, doses less than the generally accepted efficacious dose of a therapeutic agent can be used. For example, in various embodiments, the composition comprises a dosage that is less than about 10% to 75% of the generally accepted efficacious dose range. In some embodiments, at least about 10% or less of the generally accepted efficacious dose range is used, at least about 15% or less, at least about 25%, at least about 30% or less, at least about 40% or less, at least about 50% or less, at least about 60% or less, at least about 75% or less, and at least about 90%.
  • The therapeutic agents can be administered singly or sequentially, or in a cocktail with other therapeutic agents, as described below. The therapeutic agents can be administered orally, intravenously, systemically by injection intramuscularly, subcutaneously, intrathecally or intraperitoneally.
  • Examples of therapeutic agents that can be used in the compositions described herein include, but are not limited to, dexamethasone, thalidomide, melphalan, prednisone, doxorubicin, doxorubicin HCL liposome injection, bortezomib, lenalidomide, and/or combinations thereof.
  • Accordingly, in some embodiments, two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide.
  • In some embodiments, two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising a therapeutically effective amount of bortezomib.
  • In some embodiments, at least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide and a therapeutically effective amount of bortezomib. In some embodiments, lenalidomide and bortezomib are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising lenalidomide, and a third comprising bortezomib.
  • In some embodiments, at least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of lenalidomide and dexamethasone. In some embodiments, lenalidomide and dexamethasone are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising lenalidomide, and a third comprising dexamethasone.
  • In some embodiments at least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63 and a second comprising a therapeutically effective amount of bortezomib and dexamethasone. In some embodiments, bortezomib and dexamethasone are provided separately, such that a total of three pharmaceutical compositions are provided: a first comprising an anti-CS1 antibody, such as HuLuc63, a second comprising bortezomib, and a third comprising dexamethasone.
  • In some embodiments, at least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising therapeutically effective amount of lenalidomide, bortezomib, and dexamethasone. In some embodiments, lenalidomide, bortezomib, and dexamethasone are provided separately. Provided that the agents retain their efficacy, compositions comprising other combinations can be prepared, depending in part, on dosage, route of administration, and whether the agents are provided in a solid, semi-solid or liquid form. For example, a total of three compositions can be made: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, a second comprising dexamethasone, and a third comprising lenalidomide and bortezomib.
  • In some embodiments, at least two pharmaceutical compositions are provided: a first comprising a therapeutically effective amount of an anti-CS1 antibody, such as HuLuc63, and a second comprising a therapeutically effective amount of bortezomib and optionally can comprise one or more of the following agents: thalidomide, dexamethasone, melphalan, doxorubicin, doxorubicin HCl liposome injection, and/or prednisone. Provided that the agents retain their efficacy, compositions comprising various combinations of thalidomide, dexamethasone, melphalan, doxorubicin, doxorubicin HCl liposome injection, and prednisone can be prepared depending in part, on dosage, route of administration, and whether the agents are provided in a solid, semi-solid or liquid form.
  • The pharmaceutical compositions can exist as a solid, semi-solid, or liquid (e.g., suspensions or aerosols) dosage form. Typically, the compositions are administered in unit dosage forms suitable for single administration of precise dosage amounts. For example, anti-CS1 antibodies can be packaged in dosages ranging from about 1 to 1000 mg. In some embodiments, anti-CS1 antibodies can be packaged in a dosage at least about 1 mg, at least about 10 mg, at least about 20 mg, at least about 50 mg, at least about 100 mg, at least about 200 mg, at least about 300 mg, at least about 400 mg, at least about 500 mg, at least about 750 mg, at least about 1000 mg.
  • The compositions can also include, depending on the formulation desired, pharmaceutically-acceptable, nontoxic carriers or diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human administration. The diluent is selected so as not to affect the biological activity of the combination. Examples of such diluents are distilled water, physiological saline, Ringer's solution, dextrose solution, and Hank's solution.
  • In addition, the pharmaceutical composition or formulation can also include other carriers, adjuvants, or nontoxic, non-therapeutic, nonimmunogenic stabilizers and the like. Effective amounts of such diluent or carrier will be those amounts that are effective to obtain a pharmaceutically acceptable formulation in terms of solubility of components, or biological activity.
  • 5.3 Methods
  • The pharmaceutical compositions described herein find use in treating MM. Typically, the compositions can be used to treat Monoclonal Gammopathy of Undetermined Significance (MGUS), smoldering myeloma, asymptomatic MM, and symptomatic MM, ranging from newly diagnosed to late stage relapsed/refractory.
  • The compositions can be combined with other treatment strategies, i.e., autologous stem cell transplantation and allogeneic effector cell transplantation, to develop an effective treatment strategy based on the stage of myeloma being treated (see, e.g., Multiple Myeloma Research Foundation, Multiple Myeloma: Stem Cell Transplantation 1-30 (2004); U.S. Pat. Nos. 6,143,292, and 5,928,639, Igarashi, et al. Blood 2004, 104(1): 170-177, Maloney, et al. 2003, Blood, 102(9): 3447-3454, Badros, et al. 2002, J Clin Oncol., 20:1295-1303, Tricot, et al. 1996, Blood, 87(3):1196-1198; the contents of which are incorporated herein by reference).
  • The staging system most widely used since 1975 has been the Durie-Salmon system, in which the clinical stage of disease (Stage I, II, or III) is based on four measurements (see, e.g., Durie and Salmon, 1975, Cancer, 36:842-854). These four measurements are: (1) levels of monoclonal (M) protein (also known as paraprotein) in the serum and/or the urine; (2) the number of lytic bone lesions; (3) hemoglobin values; and, (4) serum calcium levels. These three stages can be further divided according to renal function, classified as A (relatively normal renal function, serum creatinine value <2.0 mg/dL) and B (abnormal renal function, creatinine value ≧2.0 mg/dL). A new, simpler alternative is the International Staging System (ISS) (see, e.g., Greipp et al., 2003, “Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group”, The Hematology). The ISS is based on the assessment of two blood test results, beta2-microglobulin (β2-M) and albumin, which separates patients into three prognostic groups irrespective of type of therapy.
  • Administration of the pharmaceutical compositions at selected dosage ranges and routes typically elicits a beneficial response as defined by the European Group for Blood and Marrow transplantation (EBMT). Table 2 lists the EBMT criteria for response.
  • TABLE 2
    EBMT/IBMTR/ABMTR1 Criteria for Response
    Complete Response No M-protein detected in serum or urine by
    immunofixation for a minimum of 6 weeks and
    fewer than 5% plasma cells in bone marrow
    Partial Response >50% reduction in serum M-protein level
    and/or 90% reduction in urine free light chain
    excretion or reduction to <200 mg/24 hrs for 6
    weeks2
    Minimal Response 25-49% reduction in serum M-protein level
    and/or 50-89% reduction in urine free light
    chain excretion which still exceeds 200 mg/24
    hrs for 6 weeks3
    No Change Not meeting the criteria or either minimal
    response or progressive disease
    Plateau No evidence of continuing myeloma-related
    organ or tissue damage, <25% change in M-
    protein levels and light chain excretion for 3
    months
    Progressive Disease Myeloma-related organ or tissue damage
    continuing despite therapy or its reappearance
    in plateau phase, >25% increase in serum M-
    protein level (>5 g/L) and/or >25% increase in
    urine M-protein level (>200 mg/24 hrs) and/
    or >25% increase in bone marrow plasma cells (at
    least 10% in absolute terms)2
    Relapse Reappearance of disease in patients previously
    in complete response, including detection of
    paraprotein by immunofixation
    1EBMT: European Group for Blood and Marrow transplantation; IBMTR: International Bone Marrow Transplant Registry; ABMTR: Autologous Blood and Marrow Transplant Registry.
    2For patients with non-secretory myeloma only, reduction of plasma cells in the bone marrow by >50% of initial number (partial response) or 25-49% of initial number (minimal response) is required.
    3In non-secretory myeloma, bone marrow plasma cells should increase by >25% and at least 10% in absolute terms; MRI examination may be helpful in selected patients.
  • Additional criteria that can be used to measure the outcome of a treatment include “near complete response” and “very good partial response”. A “near complete response” is defined as the criteria for a “complete response” (CR), but with a positive immunofixation test. A “very good partial response” is defined as a greater than 90% decrease in M protein (see, e.g., Multiple Myeloma Research Foundation, Multiple Myeloma: Treatment Overview 9 (2005)).
  • The degree to which administration of the compositions elicits a response in an individual clinically manifesting at least one symptom associated with MM, depends in part, on the severity of disease, e.g., Stage I, II, or III, and in part, on whether the patient is newly diagnosed or has late stage refractory MM. Thus, in some embodiments, administration of the pharmaceutical composition elicits a complete response.
  • In other embodiments, administration of the pharmaceutical composition elicits a very good partial response or a partial response.
  • In other embodiments, administration of the pharmaceutical composition elicits a minimal response.
  • In other embodiments, administration of the pharmaceutical composition prevents the disease from progressing, resulting in a response classified as “no change” or “plateau” by the EBMT.
  • Routes of administration and dosage ranges for compositions comprising an anti-CS1 antibody and one or more therapeutic agents for treating individuals diagnosed with MM, can be determined using art-standard techniques, such as a standard dose escalation study to identify the MTD (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the content of which is incorporated herein by reference).
  • Typically, anti-CS1 antibodies are administered intravenously. Administration of the other therapeutic agents described herein can be by any means known in the art. Such means include oral, rectal, nasal, topical (including buccal and sublingual) or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration and will depend in part, on the available dosage form. For example, therapeutic agents that are available in a pill or capsule format typically are administered orally. However, oral administration generally requires administration of a higher dose than does intravenous administration. Determination of the actual route of administration that is best in a particular case is well within the capabilities of those skilled in the art, and in part, will depend on the dose needed versus the number of times per month administration is required.
  • Factors affecting the selected dosage of an anti-CS1 antibody and the therapeutic agents used in the compositions and methods described herein, include, but are not limited to, the type of agent, the age, weight, and clinical condition of the recipient patient, and the experience and judgment of the clinician or practitioner administering the therapy. Generally, the selected dosage should be sufficient to result in no change, but preferably results in at least a minimal change. An effective amount of a pharmaceutical agent is that which provides an objectively identifiable response, e.g., minimal, partial, or complete, as noted by the clinician or other qualified observer, and as defined by the EBMT.
  • Generally, an anti-CS1 antibody, such as HuLuc63, is administered as a separate composition from the composition(s) comprising the therapeutic agents. As discussed above, the therapeutic agents can each be administered as a separate composition, or combined in a cocktail and administered as a single combined composition. In some embodiments, the compositions comprising an anti-CS1 antibody and one or more therapeutic agents are administered concurrently. In other embodiments, an anti-CS1 antibody can be administered prior to the administration of composition(s) comprising the therapeutic agent(s). In yet other embodiments, an anti-CS1 antibody is administered following the administration of composition(s) comprising the therapeutic agent(s).
  • In those embodiments in which an anti-CS1 antibody is administered prior to or following the administration of the therapeutic agents, determination of the duration between the administration of an anti-CS1 antibody and administration of the agents is well within the capabilities of those skilled in the art, and in part, will depend on the dose needed versus the number of times per month administration is required.
  • Doses of anti-CS1 antibodies used in the methods described herein typically range between 0.5 mg/kg to 20 mg/kg. Optimal doses for the therapeutic agents are the generally accepted efficacious doses, such as those described in the Physician Desk Reference, 56th Ed. (2002), Publisher Medical Economics, New Jersey. Optimal doses for agents not described in the Physician Desk Reference can be determined using a standard dose escalation study to identify the MTD (see, e.g., Richardson, et al. 2002, Blood, 100(9):3063-3067, the contents of which are incorporated herein by reference).
  • In some embodiments, an anti-CS1 antibody is present in a pharmaceutical composition at a concentration, or in a weight/volume percentage, or in a weight amount, suitable for intravenous administration at a dosage rate at least about 0.5 mg/kg, at least about 0.75 mg/kg, at least about 1 mg/kg, at least about 2 mg/kg, at least about 2.5 mg/kg, at least about 3 mg/kg, at least about 4 mg/kg, at least about 5 mg/kg, at least about 6 mg/kg, at least about 7 mg/kg, at least about 8 mg/kg, at least about 9 mg/kg, at least about 10 mg/kg, at least about 11 mg/kg, at least about 12 mg/kg, at least about 13 mg/kg, at least about 14 mg/kg, at least about 15 mg/kg, at least about 16 mg/kg, at least about 17 mg/kg, at least about 18 mg/kg, at least about 19 mg/kg, and at least about 20 mg/kg.
    • 6. EXAMPLES Example 1 HuLuc63 in Combination with Lenalidomide
  • Lenalidomide is the first of a new class of oral cancer drugs called IMiDs®. These immunomodulatory derivatives are chemically similar to thalidomide but are more potent and have a different side effect profile than thalidomide. They have multiple mechanisms of action that affect both the cancer cell and its microenvironment. Lenalidomide has been shown to induce immune responses, enhance activity of immune cells, and inhibit inflammation. For example, lenalidomide may enhance the activation of T cells and NK cells, induce production of interleukin 2 and inhibit pro-inflammatory cytokines such as tumor necrosis factor-alpha and interleukin 1-beta. Currently lenalidomide in combination with dexamethasone is approved for 2nd line therapy of multiple myeloma.
  • In Vitro ADCC Assay: Methods and Results
  • ADCC was measured by calcein-AM release assay, with sensitivity similar to traditional Cr51 assay, as described previously. After informed consent, peripheral blood mononuclear cells (PBMCs) including natural killer (NK) effector cells were isolated from leukopheresis products of normal donors or peripheral blood from MM patients. Increasing concentrations (0-10 μg/ml) of either HuLuc63 or human isotype control IgG1 MSL109 mAbs were added at effector: target (E:T) ratios of 20:1, in a final volume of 200 μl per well. In some experiments, PBMC effector cells were pretreated with lenalidomide for 3 days at 0.2 μM before HuLuc63-mediated ADCC assays were performed. After 4 h incubation, 100 μl culture supernatants were transferred to a Black ViewPlate™-96 plate and arbitrary fluorescent units (AFU) were read on a fluorometer (Wallac VICTOR2). This assay is valid only if (AFU mean maximum release−medium control release)/(AFU mean spontaneous release−medium control release)>7. Calculation of % specific lysis from triplicate experiments was done using the following equation:
  • % Specific Lysis = 100 × ( AFU mean experimental release - AFU mean spontaneous release 1 ) ( AFU mean maximal release 2 - AFU mean spontaneous release )
  • 1 Calcein-AM release by target cells in the absence of Ab or NK cells.2 Calcein-AM release by target cells upon lysis by detergent.
  • HuLuc63-mediated lysis of patient MM cells by effector cells from the same patient was measured using an ADCC assay. HuLuc63, but not iso IgG1, induced significant autologous myeloma cell lysis in patients in patient samples (FIGS. 1A-1C). HuLuc63-mediated autologous tumor cell lysis was also demonstrated in patients with MM resistant or refractory to novel anti-MM therapies including bortezomib and/or 17-AAG (targeting heat shock protein 90) (FIGS. 2A and 2B). These data suggest that HuLuc63 can target myeloma cells from patients that are newly diagnosed, or resistant to standard of care drugs and/or novel agents.
  • HuLuc63-mediated lysis of patient myeloma cells by PBMC effector cells from the same patient was measured using an ADCC assay. CD138-purified tumor cells from a patient with MM were incubated with autologous effector cells in the presence of serial dilutions of HuLuc63 (solid symbols) or isotype control IgG1 (open symbols). PBMC effector cells were pre-incubated for 3 days in the presence or absence of with lenalidomide (0.2 mM) (square symbols) or vehicle control (round symbols), followed by HuLuc63-mediated ADCC. HuLuc63-mediated ADCC, but not iso IgG1, induced significant autologous myeloma cell lysis in a patient sample. Pre-incubation of the PBMC effector cells with lenalidomide significantly increased the ADCC activity (FIG. 3C). Similarly, pretreatment of effector cells with lenalidomide enhanced HuLuc63-induced lysis of myeloma cell lines (FIGS. 3A and 3B). These results provide the framework for a treatment strategy combining lenalidomide with HuLuc63 in MM.
    • Example 2 HuLuc63 in Combination with Bortezomib
  • Bortezomib is a potent, specific, and reversible proteasome inhibitor. Proteasomes are present in all cells and function to help regulate cell growth. Inhibition of the proteasome results in apoptosis of cancer cells. Bortezomib has been shown to be particularly effective at killing myeloma cells and is currently approved for 2nd and 3rd line therapy in multiple myeloma. Recent data has shown that bortezomib treatment of myeloma cells results in down-modulation of cell-surface expression of MHC class I, an inhibitor of NK function (Shi et al., Blood (ASH Annual Meeting Abstracts), November 2006; 108:3498). The hypothesis is that bortezomib treatment of myeloma cells would make them more susceptible to NK-mediated killing and, thus, enhance HuLuc63-mediated ADCC. The purpose of this study was to examine whether using HuLuc63 in combination with bortezomib provided therapeutic benefit.
  • The effect of HuLuc63 and bortezomib treatment on expression of CS1 in MM cell lines and mouse xenograft tumors was examined by flow cytometry and immunohistochemistry respectively.
  • In Vitro ADCC Assay: Methods and Results
  • OPM2 myeloma cells were harvested at mid-log phase, suspended at a density of 1.0×106 cells/mL in complete media (RPMI with 10% FBS) and treated overnight with or without Velcade (10 nM). Cells were collected, washed, re-suspended at a density of 20×106 viable cells/mL, and labeled for one hour with 50 mCi Na2[51Cr]O4 per 106 cells. 51Cr-Labeled cells were washed then added to a 96-well V-bottomed polystyrene plate at a cell density of 15,000 cells per 75 μL RPMI supplemented with 10% heat-inactivated FBS. HuLuc63 and a human IgG1 isotype control antibody MSL-109 were added to target cells for a final antibody concentration ranging from 0.001 to 10 μg/mL. NK cells were enriched from the whole blood of healthy donors using the RosetteSep human NK cell enrichment cocktail (Stem Cell Technologies). The enriched NK cells were added to Velcade treated or untreated OPM2 cells at a ratio of 10:1. After a 4-hour incubation at 37° C., cells were centrifuged and the supernatants measured for released 51Cr. Maximum release was determined from target cells lysed with 100 mg/ml Digitonin. Antibody independent cellular cytotoxicity (AICC) was determined using target cells, plus media, plus NK cells, while spontaneous lysis was determined using 51Cr-labelled cells plus media without NK effectors.

  • % Cytotoxicity was calculated as((sample−AICC)/(Maximum−AICC)*100.
  • CS1 protein expression was examined on the OPM2 multiple myeloma cell line with no significant change in CS1 expression observed pre- or post-treatment with HuLuc63, bortezomib or with both agents. The combination of HuLuc63 with bortezomib was then tested for anti-myeloma activity in vitro using ADCC assays. The results showed that pre-treatment with bortezomib significantly enhanced HuLuc63-mediated ADCC towards OPM2 cells using NK effector cells from healthy donors. OPM2 cells were pretreated with vehicle control (square symbols) or bortezomib (10 nM; round symbols) for 18 hrs and were then subjected to HuLuc63 mediated ADCC using human NK cells from healthy donors. HuLuc63 (closed symbols) and isotype control antibody (open symbols) were used at doses ranging from 0.001-10 μg/ml. The results show that bortezomib pre-treatment significantly decreased the EC50 for HuLuc63-mediated ADCC in vitro (FIGS. 4A-4D, Table 3).
  • TABLE 3
    No Bortezomib P value
    Treatment (10 nM) (t test)
    1 0.0758 0.0106 0.04
    2 0.149 0.057 0.05
    3 0.103 0.0459 0.004
    4 0.0302 0.0207 0.0004
  • In Vivo Xenograft Mouse Model: Methods and Results
  • Six- to eight-week old female IcrTac:ICR-Prkdcscid mice obtained from Taconic Farms (Germantown, N.Y.) were inoculated with 1×107 OPM2 (American Type Culture Collection) cells into the lower right flank. Caliper measurements were performed twice weekly to calculate tumor volume using the following formula: L×W×H/2, where L (length) is the longest side of the tumor in the plane of the animal's back, W (width) is the longest measurement perpendicular to the length and in the same plane and H (height) is taken at the highest point perpendicular to the back of the animal. When tumors reached an average size of about 100 mm3, animals were randomized into 3 groups of 8-10 mice each and were treated with 1 mg/kg of antibody administered intraperitoneally twice a week for a total of 6 doses. Bortezomib was administered intraperitoneally at a dose of 0.75 mg/kg twice a week for a total of 6 doses. Tumor growth was monitored for a period of 1-2 months. Animal work was carried out under NIH guidelines (“Guide for the Care and Use of Laboratory Animals”) using protocols approved by IACUC at PDL BioPharma.
  • To examine the effect of HuLuc63 combination therapy with bortezomib in vivo, OPM2 tumor-bearing mice were treated with sub-optimal doses of HuLuc63 (1 mg/kg), or isotype control antibody twice weekly for three weeks. Bortezomib was given twice a week at 0.75 mg/kg to mice receiving either isotype control antibody or HuLuc63. The results showed significant anti-tumor activity of HuLuc63 alone and in combination with bortezomib (FIG. 5A). Mice in the combination treatment group exhibited on average 40-50% smaller tumors than in the HuLuc63 monotherapy group, and 60-70% smaller tumors than in the bortezomib group.
  • In a second experiment, HuLuc63 was combined with bortezomib in vivo, using a different dose and dosing schedule for bortezomib, while keeping the original HuLuc63 dose and dosing schedule. OPM2 cells were inoculated into the flanks of SCID mice. When tumors reached an average size of about 100 mm3, animals were randomized into 4 groups of 15 mice each and were treated with 1 mg/kg of antibody administered intraperitoneally twice a week for a total of 10 doses. Bortezomib was administered intraperitoneally at a dose of 1 mg/kg twice for weeks 1 and 2, no treatment for week 3, and 1 mg/kg twice for weeks 4 and 5 for a total of 8 doses. The intent for this dosing schedule was to more closely mimic the dosing schedule of bortezomib in the clinic, where each treatment cycle consists of 2 weeks of dosing, with one week off. Tumor growth was monitored for a period of 1-2 months.
  • The results showed significant anti-tumor activity of HuLuc63 alone, bortezomib alone and for HuLuc63 in combination with bortezomib (FIG. 5B). Mice in the combination treatment group exhibited significantly smaller tumors than mice treated with either drug alone. The data indicates that bortezomib synergizes with HuLuc63 in anti-myeloma tumor activity.
    • Example 3 Phase 1b, Open-Label, Dose-Escalation Study of HuLuc63 and Bortezomib in Multiple Myeloma Patients Following First or Second Relapse
  • The proposed Phase 1b, multi-center, open-label, multi-dose, dose escalation study will evaluate the combination of HuLuc63 and bortezomib in patients with multiple myeloma after 1st or 2nd relapse. HuLuc63 will be given by intravenous injection (IV) at up to five dose levels ranging from 2.5 mg/kg to 20 mg/kg in combination with a fixed dose of bortezomib IV at 1.0 mg/m2. Patients will receive HuLuc63 every 10 days and bortezomib will be given in 21-day cycles (twice weekly for two weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12-21)).
  • After 9 weeks of therapy (6 doses of HuLuc63, 3 cycles of bortezomib), EBMT criteria will be assessed. If a patient has progressive disease, HuLuc63 will be discontinued and bortezomib may be withdrawn or continued at the discretion of the site investigator. If the patient has responded or has stable disease at Week 9, dosing with HuLuc63 and bortezomib will continue so that a total of 24 weeks of treatment (16 doses HuLuc63, 8 cycles bortezomib) are completed or disease progression occurs. Dosing with HuLuc63 and bortezomib will continue until the data from the Week 9 visit are available.
  • Patients will receive HuLuc63 IV once every 10 days, with each dose infused over 1 hour. Bortezomib will be given as IVP for 8 three-week cycles with each cycle consisting of bortezomib on days 1, 4, 8 and 11 followed by a ten-day rest period (days 11-21). Dosing cohorts are as follows: 2.5 mg/kg HuLuc63/1.3 mg/m2 bortezomib; 5 mg/kg HuLuc63/1.3 mg/m2 bortezomib; 10 mg/kg HuLuc63/1.3 mg/m2 bortezomib; 15 mg/kg HuLuc63/1.3 mg/m2 bortezomib; and, 20 mg/kg HuLuc63/1.3 mg/m2 bortezomib.
  • HuLuc63 will be provided at a concentration of 10 mg/mL in an intravenous formulation in vials. Bortezomib will be provided as a 3.5 mg lyophilized cake or powder in a 10 mL vial, to be reconstituted with 3.5 mL normal (0.9%) saline, sodium chloride injection to 3.5 mL of 1 mg/mL of bortezomib, as per Velcade® package insert.
  • Approximately 15 to 30 patients in 5 cohorts will be enrolled in the trial. Each cohort will begin with 3 patients. If no dose-limiting toxicity (DLT) is noted within the first 6 weeks of treatment in any patient, enrollment will begin in the next higher cohort. If one patient has a DLT, 3 additional patients will be enrolled in the cohort. If no other patient in the cohort has a DLT, escalation to the next cohort may proceed. If a second patient in a cohort has a DLT, the maximum tolerated dose (MTD) has been reached.
  • A dose-limiting toxicity (DLT) is defined using the National Cancer Center Institute Common Toxicity Criteria Version 3.0 (NCI CTCAE v3.0) as a grade 4 hematologic toxicity or hyperbilirubinemia, or a grade 3 toxicity in any other system considered related to HuLuc63 or the combination of HuLuc63 and bortezomib. For dose escalation to the next cohort, 3 assessable patients must complete their first 6 weeks (4 doses HuLuc63, 2 cycles bortezomib). If a DLT occurs, an additional three assessable patients will be accrued. Patients will be monitored for safety by assessing adverse events categorized by NCI CTCAE v3.0 and patients will be monitored for clinical activity using EBMT. The maximally tolerated dose (MTD) is defined as the highest dose studied for which the incidence of DLTs is ≦33%. The highest tolerated dose will be HuLuc63 20 mg/kg+bortezomib 1.0 mg/m2 if no dose limiting toxicities are observed.
    • Example 4 Phase 1b, Multi-Center, Open-Label, Dose-Escalation Study of HuLuc63 and Lenalidomide
  • The proposed Phase 1b, multi-center, open-label, multi-dose, dose escalation study will evaluate the combination of HuLuc63 and lenalidomide in patients with multiple myeloma after 1st or 2nd relapse. HuLuc63 will be given by intravenous injection (IV) at up to five dose levels ranging from 2.5 mg/kg to 20 mg/kg in combination with a fixed dose of lenalidomide PO at 15 mg. Patients will receive HuLuc63 every 7 days and lenalidomide will be given in 28-day cycles (once daily for 21 days followed by a 7-day rest period (days 22-28)).
  • After 8 weeks of therapy (8 doses of HuLuc63, 2 cycles of lenalidomide), EBMT criteria will be assessed. Dexamethasone will be added to the regimen at an oral dose of 40 mg daily on days 1, 8, 15 and 22 of a 4-week cycle. If at week 12 (12 doses HuLuc63, 3 cycles of lenalidomide, 1 cycle of dexamethasone) there is evidence of progressive disease, HuLuc63 will be stopped and lenalidomide and dexamethasone will be continued up to 16 weeks at the discretion of the investigator. If a patient has stable disease or better, they will continue on HuLuc63 until week 16 (15 total doses) or disease progression. EMBT criteria will be evaluated at week 16.
  • Patients will receive HuLuc63 IV once every 10 days, with each dose infused over 1 hour. Lenalidomide will be given orally daily for 3 weeks followed by a weeklong rest period. Dosing cohorts are as follows: 2.5 mg/kg HuLuc63/15 mg lenalidomide; 5 mg/kg HuLuc63/15 mg lenalidomide; 10 mg/kg HuLuc63/15 mg lenalidomide; 15 mg/kg HuLuc63/15 mg lenalidomide; and, 20 mg/kg HuLuc63/15 mg lenalidomide. After week 8, dexamethasone will be added to the above regimens at an oral dose of 40 mg daily on days 1, 8, 15 and 22 of a 4 week cycle.
  • HuLuc63 will be provided at a concentration of 10 mg/mL in an intravenous formulation in vials. Lenalidomide will be supplied as 5 mg and 10 mg capsules for oral administration.
  • Approximately 15 to 30 patients in 5 cohorts will be enrolled in the trial. Each cohort will begin with 3 patients. If no dose-limiting toxicity (DLT) is noted within the first 4 weeks of treatment in any patient, enrollment will begin in the next higher cohort. If one patient has a DLT, 3 additional patients will be enrolled in the cohort. If no other patient in the cohort has a DLT, escalation to the next cohort may proceed. If a second patient in a cohort has a DLT, the maximum tolerated dose (MTD) has been reached.
  • A dose-limiting toxicity (DLT) is defined using the National Cancer Center Institute Common Toxicity Criteria Version 3.0 (NCI CTCAE v3.0) as a grade 4 hematologic toxicity or hyperbilirubinemia, or a grade 3 toxicity in any other system considered related to HuLuc63 or the combination of HuLuc63 and lenalidomide. For dose escalation to the next cohort, 3 assessable patients must complete their first 4 weeks (4 doses HuLuc63, 1 cycle lenalidomide). If a DLT occurs, an additional three assessable patients will be accrued. Patients will be monitored for safety by assessing adverse events categorized by NCI CTCAE v3.0 and patients will be monitored for clinical activity using EBMT. The maximally tolerated dose (MTD) is defined as the highest dose studied for which the incidence of DLTs is ≦33%. The highest tolerated dose will be HuLuc63 20 mg/kg+lenalidomide 15 mg if no dose limiting toxicities are observed.
  • All publications, patents, patent applications and other documents cited in this application are hereby incorporated by reference in their entireties for all purposes to the same extent as if each individual publication, patent, patent application or other document were individually indicated to be incorporated by reference for all purposes.
  • While various specific embodiments have been illustrated and described, it will be appreciated that various changes can be made without departing from the spirit and scope of the invention(s).

Claims (30)

1-63. (canceled)
64. A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody and a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide.
65. The method of claim 64, wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1.
66. The method of claim 65, wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1.
67. The method of claim 64, wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG1 antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.
68. The method of claim 64, in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
69. The method of claim 67, in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
70. The method of claim 68, in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day.
71. A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, and a therapeutically effective amount of dexamethasone.
72. The method of claim 71, wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1.
73. The method of claim 72, wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1.
74. The method of claim 71, wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 comprising a humanized IgG1 antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.
75. The method of claim 71, in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
76. The method of claim 74, in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
77. The method of claim 75, in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day.
78. A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, and a third pharmaceutical composition comprising a therapeutically effective amount of bortezomib.
79. The method of claim 78, wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1.
80. The method of claim 79, wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1.
81. The method of claim 78, wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG1 antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.
82. The method of claim 78, in which the anti-CS1 antibody is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
83. The method of claim 81, in which the HuLuc63 is administered intravenously at a dosage from approximately 0.5 mg/kg to approximately 20 mg/kg.
84. The method of claim 82, in which lenalidomide is administered orally at a dosage from approximately 1 mg/day to 50 mg/day.
85. A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of lenalidomide, a third pharmaceutical composition comprising a therapeutically effective amount of bortezomib, and a therapeutically effective amount of dexamethasone.
86. The method of claim 85, wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1.
87. The method of claim 86, wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1.
88. The method of claim 85, wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG1 antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.
89. A method of treating multiple myeloma in a subject, comprising administering to a subject in need thereof a first pharmaceutical composition comprising a therapeutically effective amount of an anti-CS1 antibody, a second pharmaceutical composition comprising a therapeutically effective amount of bortezomib, and a therapeutically effective amount of dexamethasone.
90. The method of claim 89, wherein the anti-CS1 antibody binds the epitope covered by amino acids 170 to 227 of SEQ ID NO:1.
91. The method of claim 90, wherein the anti-CS1 antibody further binds the epitope covered by amino acids 23 to 151 of SEQ ID NO:1 or the epitope covered by amino acids 68 to 151 of SEQ ID NO:1.
92. The method of claim 89, wherein the anti-CS1 antibody is HuLuc63, said HuLuc63 being a humanized IgG1 antibody comprising the heavy chain variable region of SEQ ID NO:5 and the light chain variable region of SEQ ID NO:6.
US14/139,096 2006-08-07 2013-12-23 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies Abandoned US20140322201A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/139,096 US20140322201A1 (en) 2006-08-07 2013-12-23 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US14/834,077 US20160137735A1 (en) 2006-08-07 2015-08-24 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
HUS1600043C HUS1600043I1 (en) 2006-08-07 2016-10-20 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US15/670,681 US20170342150A1 (en) 2006-08-07 2017-08-07 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83618506P 2006-08-07 2006-08-07
US94426207P 2007-06-15 2007-06-15
US11/835,257 US8632772B2 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US14/139,096 US20140322201A1 (en) 2006-08-07 2013-12-23 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/835,257 Continuation US8632772B2 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/834,077 Continuation US20160137735A1 (en) 2006-08-07 2015-08-24 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Publications (1)

Publication Number Publication Date
US20140322201A1 true US20140322201A1 (en) 2014-10-30

Family

ID=38831279

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/835,257 Active 2029-04-26 US8632772B2 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
US14/139,096 Abandoned US20140322201A1 (en) 2006-08-07 2013-12-23 Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US14/834,077 Abandoned US20160137735A1 (en) 2006-08-07 2015-08-24 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US15/670,681 Abandoned US20170342150A1 (en) 2006-08-07 2017-08-07 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/835,257 Active 2029-04-26 US8632772B2 (en) 2006-08-07 2007-08-07 Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/834,077 Abandoned US20160137735A1 (en) 2006-08-07 2015-08-24 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
US15/670,681 Abandoned US20170342150A1 (en) 2006-08-07 2017-08-07 Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies

Country Status (24)

Country Link
US (4) US8632772B2 (en)
EP (5) EP2068874B1 (en)
JP (1) JP5340935B2 (en)
CN (1) CN101686971B (en)
AU (1) AU2007281684C1 (en)
BR (1) BRPI0716647A2 (en)
CA (1) CA2660356C (en)
CY (5) CY1116247T1 (en)
DK (2) DK2641601T3 (en)
ES (2) ES2535437T3 (en)
HK (1) HK1129853A1 (en)
HR (2) HRP20150449T1 (en)
HU (4) HUE029027T2 (en)
IL (2) IL196919A (en)
LT (4) LT2641601T (en)
LU (3) LU93276I2 (en)
MX (1) MX2009001441A (en)
NL (1) NL300840I2 (en)
NO (1) NO346835B1 (en)
NZ (1) NZ574978A (en)
PL (2) PL2068874T3 (en)
PT (2) PT2068874E (en)
SI (2) SI2641601T1 (en)
WO (1) WO2008019378A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
DK2068930T3 (en) * 2006-08-07 2012-10-29 Abbott Biotherapeutics Corp Compositions and Methods Using Anti-CS1 Antibodies to Treat Multiple Myelomas
US9096681B2 (en) * 2008-06-02 2015-08-04 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides
AU2009271401A1 (en) * 2008-06-16 2010-01-21 Immunogen Inc. Novel synergistic effects
US20110236428A1 (en) * 2008-10-21 2011-09-29 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2010293383B2 (en) 2009-09-10 2014-12-18 Kyowa Kirin Co., Ltd. Medicament including antibody composition specifically bound to human CC chemokine receptor 4 (CCR4)
MX2012005849A (en) * 2009-11-24 2012-08-23 Celgene Corp Immunomodulatory compounds for the restoration of vitamin d sensitivity in vitamin d resistant tumor cells.
CN102241773B (en) * 2010-05-13 2014-05-14 四川大学 Anti-myeloma cell polyclonal antibody and preparation method thereof
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
US10494433B2 (en) 2013-11-06 2019-12-03 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
RU2697098C1 (en) * 2013-11-21 2019-08-12 Ф.Хоффманн-Ля Рош Аг Antibodies to alpha-synuclein and methods of using
RS64038B1 (en) * 2014-08-22 2023-04-28 Celgene Corp Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
WO2016049022A1 (en) * 2014-09-23 2016-03-31 Board Of Trustees Of Michigan State University Compositions and methods for modulating an immune response
WO2016054354A1 (en) 2014-10-02 2016-04-07 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating malignancies
SG11201703446RA (en) 2014-10-31 2017-05-30 Abbvie Biotherapeutics Inc Anti-cs1 antibodies and antibody drug conjugates
WO2016073184A1 (en) 2014-11-04 2016-05-12 Dana Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR20170088984A (en) * 2014-12-04 2017-08-02 브리스톨-마이어스 스큅 컴퍼니 Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)
ES2862708T3 (en) * 2015-05-13 2021-10-07 Morphosys Ag Treatment of multiple myeloma (MM)
RS62352B1 (en) * 2015-06-29 2021-10-29 Bristol Myers Squibb Co Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer
CN105688185B (en) * 2016-03-13 2019-03-19 浙江药苑生物科技有限公司 It is a kind of for treating the medical composition and its use of myelosis, osteocarcinoma
WO2018182529A1 (en) * 2017-03-29 2018-10-04 Agency For Science, Technology And Research Anti oligosaccharide antibody
EP3714257A4 (en) * 2017-11-22 2021-08-11 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112969A (en) 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
CA2220971A1 (en) 1995-05-25 1996-11-28 Baxter International Inc. Allogeneic cell therapy for cancer following allogeneic stem cell transplantation
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
ATE459357T1 (en) * 2002-05-17 2010-03-15 Celgene Corp COMBINATIONS FOR TREATING MULTIPLE MYELOMA
US7709610B2 (en) * 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CA2595398A1 (en) * 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies
WO2008019379A2 (en) 2006-08-07 2008-02-14 Pdl Biopharma, Inc. Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
AU2007281684C1 (en) 2006-08-07 2013-12-19 Abbvie Biotherapeutics Inc. Methods of treating multiple myeloma using combination therapies based on anti-CS1 antibodies
DK2068930T3 (en) * 2006-08-07 2012-10-29 Abbott Biotherapeutics Corp Compositions and Methods Using Anti-CS1 Antibodies to Treat Multiple Myelomas

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021092044A1 (en) 2019-11-05 2021-05-14 Bristol-Myers Squibb Company M-protein assays and uses thereof

Also Published As

Publication number Publication date
ES2589302T3 (en) 2016-11-11
CN101686971A (en) 2010-03-31
CY2016037I1 (en) 2017-07-12
CY2016038I1 (en) 2017-07-12
LU93275I2 (en) 2016-12-27
CY2016036I2 (en) 2017-07-12
EP2942057A1 (en) 2015-11-11
NO346835B1 (en) 2023-01-23
IL243933A0 (en) 2016-04-21
SI2068874T1 (en) 2015-06-30
NZ574978A (en) 2012-08-31
AU2007281684A1 (en) 2008-02-14
DK2641601T3 (en) 2016-08-22
AU2007281684B2 (en) 2013-05-16
HRP20150449T1 (en) 2015-06-05
HUS1600043I1 (en) 2016-12-28
IL196919A0 (en) 2009-11-18
JP5340935B2 (en) 2013-11-13
BRPI0716647A2 (en) 2017-05-16
NL300840I2 (en) 2017-01-03
HUS1600044I1 (en) 2016-12-28
EP2641601A1 (en) 2013-09-25
AU2007281684C1 (en) 2013-12-19
HUS1600045I1 (en) 2016-12-28
CY1117992T1 (en) 2017-05-17
CN101686971B (en) 2013-09-11
PL2641601T3 (en) 2017-01-31
LTPA2016030I1 (en) 2016-11-10
ES2535437T3 (en) 2015-05-11
PT2641601T (en) 2016-10-14
US20080152646A1 (en) 2008-06-26
LT2641601T (en) 2016-10-10
JP2010500371A (en) 2010-01-07
HK1129853A1 (en) 2009-12-11
LTPA2016029I1 (en) 2016-11-10
PT2068874E (en) 2015-05-21
NO20090968L (en) 2009-04-30
CY2016036I1 (en) 2017-07-12
CY1116247T1 (en) 2017-02-08
US20160137735A1 (en) 2016-05-19
LU93277I2 (en) 2016-12-27
HRP20161284T1 (en) 2016-12-16
SI2641601T1 (en) 2016-11-30
EP2641601B1 (en) 2016-07-06
MX2009001441A (en) 2009-07-06
EP3115049A1 (en) 2017-01-11
HUE029027T2 (en) 2017-01-30
US20170342150A1 (en) 2017-11-30
CA2660356C (en) 2016-04-05
CA2660356A1 (en) 2008-02-14
EP2641600A1 (en) 2013-09-25
LTPA2016031I1 (en) 2016-11-10
US8632772B2 (en) 2014-01-21
LU93276I2 (en) 2016-12-27
WO2008019378A1 (en) 2008-02-14
LTC2068874I2 (en) 2018-11-12
EP2641601B8 (en) 2016-09-21
PL2068874T3 (en) 2015-06-30
DK2068874T3 (en) 2015-04-27
EP2068874A1 (en) 2009-06-17
EP2068874B1 (en) 2015-01-28
IL196919A (en) 2016-03-31

Similar Documents

Publication Publication Date Title
US20170342150A1 (en) Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
AU2007281682B2 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
WO2008019379A2 (en) Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells
AU2020339737A1 (en) Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION